“Gothenburg is interesting since prices for space is relatively low. It’s also the geographical midpoint in the Nordics, close to both Copenhagen and Oslo to where you can drive, and has a talent pool of people,” says Martin Bergman, Country Manager Nordic and Baltic at Indivior.
Indivior, a FTSE 250 company, is a leader in opoid addiction treatment. The company already has customers, mainly addiction clinics, in Sweden, Finland and elsewhere in the Nordics.
According to Martin Bergman, there are plans to hire more staff at the new Gothenburg office.
“Indivior is looking to hire talents into the company for the growing business in addiction and the opportunities the company has to put new compounds on the market to create a much better platform for addiction patients to be treated.”
The company moves into the new office, located in Gårda in Gothenburg’s inner east, on 1 December.
Are you satisfied with the support you have received from Business Region Göteborg so far?
“It has been great to work with Business Region Göteborg to find sharp arguments for the office location but also to discuss the opportunity Indivior has in this region,” says Martin Bergman.
Can you tell us more about Indivior?
“Indivior began with the goal of addressing the lack of treatment for the worldwide problem of addiction. In 1994, RB established the Buprenorphine Business Group, to which Indivior can trace its history of over 20 years. The buprenorphine Business Group focused on developing buprenorphine for the treatment of opioid dependence. Even though it was an area of business that was unproven, we believed we could make a measurable difference in the lives of patients all over the world,” says Martin Bergman.
“Through a grassroots effort, we’ve partnered with and educated governments, policy makers, payers, and healthcare professionals about diseases of addiction and the value of alternative treatment options (including office-based treatment). We’ve also worked diligently and strategically to identify and address the unmet treatment needs of patients,” he adds.